StockData
Autolus Therapeutics plc logo

Autolus Therapeutics plc (AUTL) stock

AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3020% below fair value
$1.09−0.05 (-4.39%)

Close on Nov 17, 2026Market cap $290.12MP/E –Yield –

Autolus Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Autolus Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $112.63M, down 10.1% year over year. For fiscal 2025 it was $117.69M, down 15.0% from the year before. The highest annual figure on record is $138.44M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$117.69M-15.0%
FY2024Dec 31, 2024$138.44M+6.1%
FY2023Dec 31, 2023$130.48M+11.2%
FY2022Dec 31, 2022$117.35M+5.9%
FY2021Dec 31, 2021$110.84M-17.8%
FY2020Dec 31, 2020$134.89M+273.1%
FY2018Sep 30, 2018$36.15M+125.8%
FY2017Sep 30, 2017$16.01M+53.4%
FY2016Sep 30, 2016$10.44M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026$27.90M+1.7%
Q1 FY2026CQ1 2026Mar 31, 2026$21.21M-20.7%
Q4 FY2025CQ4 2025Dec 31, 2025$35.63M+15.6%
Q3 FY2025CQ3 2025Sep 30, 2025$27.89M-30.8%
Q2 FY2025CQ2 2025Jun 30, 2025$27.43M-25.1%
Q1 FY2025CQ1 2025Mar 31, 2025$26.73M-12.8%
Q4 FY2024CQ4 2024Dec 31, 2024$30.83M-17.9%
Q3 FY2024CQ3 2024Sep 30, 2024$40.32M+24.8%
Q2 FY2024CQ2 2024Jun 30, 2024$36.61M+10.2%
Q1 FY2024CQ1 2024Mar 31, 2024$30.67M+12.0%
Q4 FY2023CQ4 2023Dec 31, 2023$37.54M+397.4%
Q3 FY2023CQ3 2023Sep 30, 2023$32.32M+2.6%
Q2 FY2023CQ2 2023Jun 30, 2023$33.23M+7.9%
Q1 FY2023CQ1 2023Mar 31, 2023$27.39M-3.4%
Q4 FY2022CQ4 2022Dec 31, 2022$7.55M-75.4%
Q3 FY2022CQ3 2022Sep 30, 2022$31.49M-18.7%
Q2 FY2022CQ2 2022Jun 30, 2022$30.79M-8.2%
Q1 FY2022CQ1 2022Mar 31, 2022$28.37M-9.5%
Q1 FY2021CQ1 2021Mar 31, 2021$30.73M-1.8%
Q4 FY2020CQ4 2020Dec 31, 2020$38.73M+283.6%
Q3 FY2020CQ3 2020Sep 30, 2020$33.55M+278.5%
Q2 FY2020CQ2 2020Jun 30, 2020$31.33M+463.0%
Q1 FY2020CQ1 2020Mar 31, 2020$31.29M–
Q4 FY2018CQ3 2018Sep 30, 2018$10.10M–
Q3 FY2018CQ2 2018Jun 30, 2018$8.86M–
Q1 FY2018CQ4 2017Dec 31, 2017$5.56M–

More Autolus Therapeutics figures

See a number that looks wrong?